Bausch Health reports loss
Bausch Health Companies Inc. reported a loss of $350 million in its latest quarter as its revenue moved lower.
From the Biotech Insider archive. This article dates from Nov 7, 2018 and is preserved as first published.
Bausch Health Companies Inc. reported a loss of $350 million in its latest quarter as its revenue moved lower.
The company formerly known as Valeant Pharmaceuticals says the loss for the quarter ended Sept. 30 amounted to $1.00 per diluted share.
The company formerly known as Valeant Pharmaceuticals says the loss for the quarter ended Sept.
The result compared with a profit of $1.30 billion or $3.69 per share in the same period a year earlier when it benefited from internal tax reorganization.
Revenue totalled nearly $2.14 billion for the quarter, down from nearly $2.22 billion a year ago.
On an adjusted basis, Bausch Health says it earned $403 million in its most recent quarter, up from $367 million in the third quarter of 2017.
The company says the increase was primarily due to lower interest costs and a lower tax rate.
